The benefits of Wegovy that go beyond losing weight

Cardiovascular protection: what the SELECT trial showed

The clearest evidence for a benefit beyond weight loss comes from the SELECT trial, a large randomised controlled study involving over 17,000 adults with obesity or overweight and a history of cardiovascular disease but without type 2 diabetes. Participants received semaglutide 2.4mg or placebo over roughly five years. The result was a statistically significant 20% relative reduction in the composite risk of cardiovascular death, non-fatal heart attack and non-fatal stroke in those receiving semaglutide.

What made this finding particularly striking to researchers was that much of the protective effect appeared to operate independently of the degree of weight lost. That points to mechanisms beyond simple caloric reduction: reduced systemic inflammation, improvements in lipid profiles and direct effects on vascular function have all been proposed, though the precise pathways are still being investigated. NICE's appraisal process for semaglutide noted the cardiovascular data as part of the broader clinical picture when considering its use in weight management.

It's worth being precise here: this cardiovascular indication applies to adults with established heart disease. It does not mean everyone using Wegovy for weight management will experience the same degree of risk reduction. A prescriber weighs up your individual history. If weight loss is your primary goal, that remains a separate clinical consideration to the cardiovascular indication.

Liver disease: the July 2026 MASH approval

On 3 July 2026 the MHRA granted semaglutide (Wegovy) conditional approval for the treatment of metabolic dysfunction-associated steatohepatitis with moderate-to-advanced fibrosis in adults. MASH is a serious progressive liver disease linked to excess fat accumulation; left untreated, it can advance to cirrhosis. Until this approval, no medicine had been specifically licensed for it in the UK.

The MHRA's announcement on 3 July 2026 confirmed this as a conditional marketing authorisation, meaning the manufacturer is required to submit further data as a condition of the licence. Clinical trials demonstrated meaningful reductions in liver inflammation and fibrosis scores compared to placebo. For patients managing both obesity and MASH, this represents a significant development in treatment options.

At nume, our prescribers assess Wegovy for weight management, which remains the primary indication relevant to our service. The MASH approval is an important scientific development, and if you have questions about liver health alongside weight management, our clinical team can discuss what is clinically appropriate for your situation.

Other emerging areas: sleep apnoea, blood pressure and inflammation

The research picture continues to grow. Separate clinical programmes have examined semaglutide's effect on obstructive sleep apnoea. Trial data reported in 2024 showed meaningful reductions in the apnoea-hypopnoea index (a measure of how often breathing is disrupted during sleep) in adults using semaglutide compared to placebo, reductions that went beyond what would be expected from weight change alone in some analyses.

Blood pressure improvements have been observed consistently across Wegovy trials, which is relevant given that hypertension is one of the weight-related conditions that affects eligibility for private prescribing. Markers of systemic inflammation, including C-reactive protein, have also fallen in treated groups. Whether these effects translate into long-term clinical outcomes at the population level is still being established.

You can read more about the full range of health effects being studied in semaglutide research on our dedicated page. Keep in mind that these emerging findings inform clinical practice but do not on their own determine whether Wegovy is appropriate for any individual. That decision belongs to a prescriber who has reviewed your full health history.

What this means in practice if you're considering Wegovy

The growing evidence base reinforces that semaglutide is not simply a weight-loss medicine that happens to sit in the fridge door, and our page on the benefits of Wegovy beyond weight loss explores how the clinical picture extends well beyond the number on the scales. For many people, the clinical rationale for treatment extends to meaningful reductions in serious health risks, which is precisely why UK regulations require a prescription and clinical assessment rather than over-the-counter access.

Private eligibility for Wegovy requires a BMI of 30 or above, or 27 or above alongside a qualifying weight-related condition such as high blood pressure, high cholesterol or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. The full overview of Wegovy's licensed use in the UK covers eligibility in more detail, and our frequently asked questions address many of the practical points patients raise before starting.

If cost is a consideration, the Wegovy cost page explains how private pricing works and what is included at nume. Treatment pricing varies by dose and provider; what matters is that prescription, clinical review and aftercare are all part of what you're paying for, not optional extras.

The NHS evidence page at NHS.uk's semaglutide section gives a reliable, plain-language summary of what semaglutide does and who it has been studied in, a good starting point alongside talking to a clinician, and our page covering the broader clinical benefits of semaglutide goes into greater depth for those who want more detail before speaking to a prescriber. Our prescribers are available seven days a week for aftercare questions once you're on treatment. To discuss whether Wegovy is right for your situation, speak to our prescribers via a free consultation.